Ronnda L. Bartel, Ph.D. Joins Aastrom Biosciences as Vice President Research & Development
16 October 2006 - 10:00PM
PR Newswire (US)
- Appointment Brings Strong Product Development Leadership to
Company - ANN ARBOR, Mich., Oct. 16 /PRNewswire-FirstCall/ --
Aastrom Biosciences, Inc. (NASDAQ:ASTM) today announced that Ronnda
L. Bartel, Ph.D. has joined the Company as Vice President of
Research and Development. Dr. Bartel is responsible for the product
development and manufacturing of Aastrom's TRC-based cell products,
as well as the Company's discovery and research efforts. Her broad
experience and leadership in the biotechnology and pharmaceutical
industries, along with experience in the manufacturing and
marketing of new cell-based products, strongly support and
complement the Company's progress in moving its tissue regeneration
products through the commercialization process. (Logo:
http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO ) Dr.
Bartel is a seasoned scientist with more than 20 years of research
and product development experience in the biotech, pharmaceutical,
diagnostic and device sectors. During this time she held several
management positions including: Senior Principal Scientist, Cell
Biology at Advanced Tissue Sciences; Vice President, Scientific
Development and Senior Director, Stem Cell Development at Stem
Cells, Inc.; Senior Director, Science and Technology at SRS
Capital, LLC; and, most recently, Executive Director, Biological
Research at MicroIslet, Inc. She has also held positions in
clinical development, drug delivery, business development and
manufacturing. Dr. Bartel holds a Ph.D. in Biochemistry from the
University of Kansas, completed postdoctoral work at the University
of Michigan and received a B.A. in Chemistry and Biology from Tabor
College. "We are very pleased to welcome Dr. Bartel to Aastrom as
our new Vice President of Research and Development," said George W.
Dunbar, President and Chief Executive Officer of Aastrom. "Ronnda's
experience in developing cell-based products, as well as
establishing and improving manufacturing processes, are essential
to our commitment of moving Aastrom's tissue regeneration cell
products through the development stage and into the market place.
In addition, her clinical, scientific, and management skills will
drive our research programs which are necessary to expand our own
expertise, and to influence the field of regenerative medicine."
Aastrom also announced that Janet M. Hock, B.D.S., Ph.D., Vice
President of Global Research and CSO, has accepted the position as
founding Director of the Maine Institute for Human Genetics and
Health, a new program in cancer, genetics and regenerative
medicine, supported by Eastern Maine Healthcare Systems, in
collaboration with Jackson Laboratory and the University of Maine.
Mr. Dunbar concluded, "We appreciate the contributions Dr. Hock has
made towards Aastrom's research advancements, and wish her well as
she pursues new endeavors in the field of scientific research."
About Aastrom Biosciences, Inc. Aastrom Biosciences, Inc.
(NASDAQ:ASTM) is developing autologous cell products for the repair
or regeneration of multiple human tissues, based on its proprietary
Tissue Repair Cell (TRC) technology. Aastrom's TRC-based products
are a unique cell mixture containing stromal, stem and progenitor
cell populations, produced outside the body from a small amount of
bone marrow taken from the patient. TRC-based products have been
used in over 225 patients, and are currently in clinical trials for
bone regeneration (long bone fractures and spine fusion) and
vascular regeneration (critical limb ischemia) applications. The
Company has reported positive interim clinical trial results for
TRCs suggesting both the clinical safety and the ability of TRCs to
induce tissue regeneration in long bone fractures and jaw bone
reconstruction. Recently, the Company's proprietary TRCs received
an Orphan Drug Designation from the U.S. Food and Drug
Administration (FDA) for use in the treatment of osteonecrosis of
the femoral head. In addition, Aastrom is developing plans for a
TRC-based therapy for cardiac regeneration. For more information,
visit Aastrom's website at http://www.aastrom.com/. This document
contains forward-looking statements, including without limitation,
statements concerning planned clinical trials, product development
objectives, and potential product applications, which involve
certain risks and uncertainties. The forward-looking statements are
also identified through use of the word "plans," and other words of
similar meaning. Actual results may differ significantly from the
expectations contained in the forward- looking statements. Among
the factors that may result in differences are potential patient
accrual difficulties, clinical trial results, potential product
development difficulties, the effects of competitive therapies,
regulatory approval requirements, the availability of financial and
other resources and the allocation of resources among different
potential uses. These and other significant factors are discussed
in greater detail in Aastrom's Annual Report on Form 10-K and other
filings with the Securities and Exchange Commission. CONTACTS: Kris
M. Maly Cameron Associates Investor Relations Department Kevin
McGrath Aastrom Biosciences, Inc. Phone: (212) 245-4577 Phone:
(734) 930-5777 Deanne Eagle (Media) Phone: (212) 554-5463
http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO
http://photoarchive.ap.org/ DATASOURCE: Aastrom Biosciences, Inc.
CONTACT: Kris M. Maly, Investor Relations Department, Aastrom
Biosciences, Inc., +1-734-930-5777; or Kevin McGrath of Cameron
Associates, +1-212-245-4577, or Media, Deanne Eagle,
+1-212-554-5463, for Aastrom Biosciences, Inc. Web site:
http://www.aastrom.com/
Copyright
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024